Leqembi At-Home Starting Dose: What FDA Approved in 2026
The FDA approved a subcutaneous starting regimen for Leqembi IQLIK that can be administered at home by a patient or caregiver, while retaining important screening and safety requirements.
Timeline
- First 18 months: The pivotal efficacy evidence used intravenous lecanemab every two weeks during the initial treatment period.
- July 13, 2026: FDA approved the subcutaneous Leqembi IQLIK starting regimen for home administration.
- After 18 months: Patients may continue with an approved intravenous or subcutaneous maintenance regimen under medical care.
On July 13, 2026, the U.S. Food and Drug Administration approved a new starting dosage regimen for Leqembi IQLIK, the subcutaneous form of lecanemab. The regimen allows an eligible adult patient or a caregiver to administer the medicine at home. It was the first FDA-approved option that allowed Leqembi treatment to begin this way rather than with clinic-based intravenous infusions. [1][2]
Leqembi is an amyloid beta-directed antibody used for Alzheimer's disease. Its goal is to reduce amyloid plaques, one biological feature associated with the disease. The large effectiveness trial behind the treatment studied intravenous lecanemab at 10 milligrams per kilogram every two weeks for 18 months in people with confirmed amyloid pathology and early symptomatic disease. [1]
The new subcutaneous starting form was not supported by a separate large clinical-outcomes trial identical to the intravenous study. FDA said the approval relied on the established effectiveness of intravenous lecanemab together with evidence that subcutaneous dosing produced comparable drug exposure and amyloid reduction. That distinction matters when interpreting what the agency approved and how the evidence was assembled. [1]
At-home administration does not mean the treatment is available without a prescription or without medical oversight. A clinician still has to determine whether treatment is appropriate, discuss risks, arrange the required monitoring and manage possible adverse effects. After the initial 18-month period, FDA says patients may transition to an approved intravenous or subcutaneous maintenance regimen. [1]
The most prominent safety concern is amyloid-related imaging abnormalities, or ARIA. These abnormalities can involve temporary swelling in areas of the brain or small spots of bleeding, and they are often detected on imaging without symptoms. They can sometimes cause serious or life-threatening effects. Headache and infusion-related reactions were also among the commonly reported adverse effects in the intravenous studies. [1]
FDA's boxed warning notes that people with two copies of the ApoE epsilon 4 gene have a higher incidence of ARIA. The prescribing information says testing should be performed before treatment to help inform risk discussions. The agency also highlights caution for patients receiving anticoagulants and lists serious hypersensitivity to lecanemab or its ingredients as a contraindication. [1]
The practical change is about access and administration: some patients may avoid repeated trips to an infusion center at the start of therapy. The medical framework remains substantial because the medicine targets brain amyloid and carries important risks. Patients and caregivers need instructions specific to the approved product and should make treatment decisions with the prescribing clinical team rather than treating home use as a signal that monitoring is optional. [1][2]
Sources
- FDA — Approval of the first at-home starting dose for an Alzheimer's treatment
- FDA — Notable drug approvals